Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation

Future Cardiology
Olga Gavín SebastiánLuis Palomera Bernal

Abstract

To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit. Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain. Overall, 243 patients (mean age 78.4 ± 10.1 years; 47.5% women, CHA2DS2-VASc 3.7 ± 1.5) were included. After a mean follow-up of 16.5 ± 12.7 months, rivaroxaban was discontinued in only 2.4% of patients. During the follow-up, seven (2.0 events/100 patient-years) patients had a thromboembolic event and six patients (1.7 events/100 patient-years) a major bleeding. Rivaroxaban was effective and safe among AF patients treated in a hematology unit, with very low discontinuation rates.

References

Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Apr 17, 2015·Thrombosis and Haemostasis·John W Eikelboom, Jeffrey I Weitz
Jan 1, 2014·BMJ Quality Improvement Reports·Thomas Davies, Ryan Geleit
Feb 26, 2016·Journal of the American Heart Association·Xiaoxi YaoPeter A Noseworthy
Mar 5, 2016·Circulation. Cardiovascular Quality and Outcomes·Geoffrey D BarnesJames B Froehlich
Aug 28, 2016·European Heart Journal·Paulus KirchhofUNKNOWN ESC Scientific Document Group
Oct 21, 2016·Journal of Thrombosis and Thrombolysis·Molly HowardBetsy Bryant Shilliday
Jan 6, 2017·The Journal of the American Osteopathic Association·Salma I PatelFadi Shamoun
May 16, 2017·Internal and Emergency Medicine·Gualtiero PalaretiUNKNOWN centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulan
May 20, 2017·Journal of the American College of Cardiology·Lucas N MarzecThomas M Maddox
May 23, 2017·Journal of Managed Care & Specialty Pharmacy·JaeJin AnGustavus Aranda
Aug 31, 2017·Journal of Managed Care & Specialty Pharmacy·Colleen A McHorneyEric D Peterson
Oct 19, 2017·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·A John CammEric Peterson
Nov 3, 2017·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·María Asunción Esteve-PastorUNKNOWN FANTASIIA Investigators

❮ Previous
Next ❯

Citations

Aug 31, 2019·Future Cardiology·Olga Gavín SebastiánLuis Palomera Bernal

❮ Previous
Next ❯

Software Mentioned

SILVER
XANTUS
SPSS
AP

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.